Abbott and YRGCARE, a leading non-profit offering non-stigmatizing, high-quality services to those with or at risk for HIV (Human Immunodeficiency Virus), opened two new facilities dedicated to helping stop the spread of HIV. The initiative aims to transform the lives of over 2500 people in these cities over the next year by taking a holistic approach for those who have or are at-risk for HIV and other known or emerging infectious diseases.
ABBOTT PARK, Ill. and BETHESDA, Md., June 20, 2024 /PRNewswire/ -- The global healthcare company Abbott (NYSE: ABT) and the National Association of Community Health Centers (NACHC) have joined together to increase access to healthy foods and improve health through the Innovation Incubator initiative. Eight community health centers have been selected to receive funding, expert guidance and training to design and test new solutions to help advance nutrition and improve care in their communities.
ABBOTT PARK, Ill., June 14, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share.This marks the 402nd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2024, to shareholders of record at the close of business on July 15, 2024.
Abbott announced it has received CE Mark in Europe for the AVEIR dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacemaker that treats people with abnormal or slow heart rhythms.
ABBOTT PARK, Ill., June 10, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems – Lingo™ and Libre Rio™, which are based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology1, now used by about 6 million people globally2. The newly cleared systems have been intentionally designed to meet different needs – Lingo for consumers who want to better understand and improve their health and wellness, and Libre Rio for adults with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.
Nearly a year after garnering an FDA nod, Abbott’s wireless, dual-chamber pacemaker system is crossing the pond with a CE Mark approval in Europe.
Abbott Laboratories loses bid to halt Glucerna class action
The Multi Disciplinary Committee of Experts (MDC), which advices the National Pharmaceutical Pricing Authority (NPPA) on pricing related matters, has rejected an application by pharma major Abbott Healthcare for special retail price on its antibiotic drug combination flagyl gel with soft adapter tip applicator claiming that the product comes with incremental innovation.
Abbott India Limited has reported standalone financial results for the period ended March 31, 2024.
ABBOTT PARK, Ill., April 29, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.